journal article·2024-08Open access

Allicin‒Decorated FeO1‐xOH Nanocatalytic Medicine for Fe2+/Fe3+ Cycling‒Promoted Efficient and Sustained Tumor Regression

Zhongming Jie, Bingyan Xiong, Jianlin Shi

Advanced Science· Volume 11· Issue 32

Abstract

Abstract In the tumor treatment by Fenton reaction‒based nanocatalytic medicines, the gradual consumption of Fe(II) ions greatly reduces the production of hydroxyl radicals, one of the most active reactive oxygen species (ROS), leading to much deteriorated therapeutic efficacy. Meanwhile, the ROS consumption caused by the highly expressed reduced glutathione (GSH) in the tumor microenvironment further prevents tumor apoptosis. Therefore, using the highly expressed GSH in tumor tissue to promote the Fe(III) reduction to Fe(II) can not only weaken the resistance of tumor to ROS attack, but also generate enough Fe(II) to accelerate the Fenton reaction. In view of this, an allicin‒modified FeO1‐xOH nanocatalyst possessing varied valence states (II, III) has been designed and synthesized. The coexistence of Fe(II)/Fe(III) enables the simultaneous occurrence of Fenton reaction and GSH oxidation, and the Fe(III) reduction by GSH oxidation results in the promoted cyclic conversion of Fe ions in tumor and positive catalytic therapeutic effects. Moreover, allicin capable of regulating cell cycle and suppressing tumor growth is loaded on FeO1‐xOH nanosheets to activate immune response against tumors and inhibit tumor recurrence, finally achieving the tumor regression efficiently and sustainably. This therapeutic strategy provides an innovative approach to formulate efficient antitumor nanomedicine for enhanced tumor treatment.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanocluster Synthesis and Applications · Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Shanghai Tenth People's Hospital Shanghai Frontiers Science Center of Nanocatalytic Medicine School of Medicine Tongji University Shanghai 200072 P. R. China

School of Physical Science and Technology ShanghaiTech University Shanghai 201210 P. R. China

Shanghai Institute of Ceramics Chinese Academy of Sciences Research Unit of Nanocatalytic Medicine in Specific Therapy for Serious Disease Chinese Academy of Medical Sciences (2021RU012) Shanghai 200050 P. R. China

Center of Materials Science and Optoelectronics Engineering University of Chinese Academy of Sciences Beijing 100049 P. R. China

Funding

Fundamental Research Funds for the Central Universities · National Key Research and Development Program of China · Shanghai Municipal Health Commission · National Natural Science Foundation of China

References (41)

Show source-provided references
1. Lee F. Y. · Cancer Res. · 1989 · 49 · 5244
2. 10.1016/0005-2728(87)90206-410.1016/0005-2728(87)90206-4 ↗
3. 10.1016/j.addr.2009.02.00510.1016/j.addr.2009.02.005 ↗
4. 10.1038/s12276-018-0159-110.1038/s12276-018-0159-1 ↗
5. Li Y. · Technol. Cancer Res. Treat. · 2021 · 20 · 1533
6. 10.1016/j.apmt.2020.10086410.1016/j.apmt.2020.100864 ↗
7. 10.1186/s12951-021-01181-z10.1186/s12951-021-01181-z ↗
8. 10.1002/anie.20180566410.1002/anie.201805664 ↗
9. 10.31635/ccschem.020.20200051910.31635/ccschem.020.202000519 ↗
10. 10.1016/j.freeradbiomed.2010.03.02510.1016/j.freeradbiomed.2010.03.025 ↗
11. 10.1016/S0968-0004(03)00174-910.1016/S0968-0004(03)00174-9 ↗
12. 10.1016/j.freeradbiomed.2009.12.02210.1016/j.freeradbiomed.2009.12.022 ↗
13. 10.1038/s41568-021-00435-010.1038/s41568-021-00435-0 ↗
14. 10.1039/c3cs60024f10.1039/c3cs60024f ↗
15. Estrela J. M. · Crit. Rev. Clin. Lab. Sci. · 2008 · 33 · 143
16. 10.1002/adhm.20210192610.1002/adhm.202101926 ↗
17. 10.1021/acsbiomaterials.0c0100910.1021/acsbiomaterials.0c01009 ↗
18. 10.1016/j.semcancer.2017.02.01110.1016/j.semcancer.2017.02.011 ↗
19. 10.1016/j.tcb.2021.05.00110.1016/j.tcb.2021.05.001 ↗
20. 10.1016/j.phrs.2022.10611810.1016/j.phrs.2022.106118 ↗
21. 10.1016/j.addr.2017.07.01510.1016/j.addr.2017.07.015 ↗
22. 10.3390/molecules2609240910.3390/molecules26092409 ↗
23. 10.1016/j.ccr.2017.01.00910.1016/j.ccr.2017.01.009 ↗
24. 10.1016/j.cej.2017.10.09210.1016/j.cej.2017.10.092 ↗
25. Teo B. K. · Inorg. Chem. · 2007 · 9 · 15
26. 10.1021/jacs.3c0371710.1021/jacs.3c03717 ↗
27. 10.1038/s41565-018-0185-010.1038/s41565-018-0185-0 ↗
28. 10.1002/adfm.20221125110.1002/adfm.202211251 ↗
29. 10.3389/fphar.2020.0106110.3389/fphar.2020.01061 ↗
30. 10.1016/j.ccell.2019.04.00210.1016/j.ccell.2019.04.002 ↗
31. 10.1038/s41575-021-00486-610.1038/s41575-021-00486-6 ↗
32. 10.1038/s41422-020-00441-110.1038/s41422-020-00441-1 ↗
33. 10.1146/annurev-immunol-042617-05301010.1146/annurev-immunol-042617-053010 ↗
34. 10.1016/j.trecan.2017.10.00610.1016/j.trecan.2017.10.006 ↗
35. 10.1042/BSR2018099210.1042/BSR20180992 ↗
36. 10.1016/j.immuni.2018.03.01710.1016/j.immuni.2018.03.017 ↗
37. 10.1038/s43018-022-00468-w10.1038/s43018-022-00468-w ↗
38. 10.1002/anie.20221458610.1002/anie.202214586 ↗
39. 10.1021/jacs.1c1188610.1021/jacs.1c11886 ↗
40. 10.1038/s41467-019-11269-810.1038/s41467-019-11269-8 ↗
41. 10.1002/advs.20220449810.1002/advs.202204498 ↗